Core Framework & Diagram What Is Immune Engineering?
7 月 23, 20261 Min Read What Is Synthetic Immunology?
7 月 23, 2026No longer waiting for the immune system to get stronger on its own — we're starting to directly redesign it
—— Immune Engineering: from CAR-T to gene editing, a field rewriting medical rules.
I. CAR-T: transforming ordinary soldiers into precision-guided missiles
Chimeric Antigen Receptor T cells (CAR-T) are the most commercially mature, clinically evidence-rich products in immune engineering so far. Understanding how CAR-T works is the best entry point to understanding the entire immune engineering field. In their natural state, T cells recognizing target cells require target cells to display specific antigen peptides using MHC molecules. This process has multiple limitations: cancer cells can evade T cells by downregulating MHC; T cell receptor diversity limits the antigen range any single T cell can recognize; T cell activation also requires co-stimulatory signals (CD28, etc.).
CAR bypasses all these limitations. It's a completely synthetic protein with three components: an extracellular domain (antigen-binding domain) — usually from an antibody's single-chain variable fragment (scFv), directly recognizing target antigens without needing MHC; a transmembrane domain — anchoring CAR to the cell membrane; and an intracellular signaling domain — containing CD3-zeta (providing activation signal) and co-stimulatory domains (CD28 or 4-1BB, providing sustained activation signal). Introducing CAR's gene into T cells via retroviral or lentiviral vectors makes T cells into CAR-T cells — a directed warrior that can directly recognize target antigens (without MHC) and after activation efficiently kill target cells. CD19-CAR-T (targeting CD19 protein on B cell surfaces) was the first FDA-approved CAR-T product (Tisagenlecleucel/Kymriah, 2017). In pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) patients, complete remission rates exceeded eighty percent — achieving long-term survival in a patient population previously with almost no treatment options.
|
CAR-T is immune engineering's first mature product, proving that 'modifying immune cells to treat diseases' isn't just theoretically feasible but has real, life-changing clinical effects. |
2. CAR-NK: CAR-T's 'friendlier' sibling
CAR-T's clinical success also exposed several substantial limitations: individual manufacturing (each batch requires taking T cells from each patient, manufacturing over weeks, then returning them — long manufacturing time, extremely high cost, and some patients have poor T cell quality due to disease or treatment, making manufacturing fail); cytokine release syndrome (CRS, severe and potentially life-threatening after CAR-T activation); neurotoxicity (ICANS); and graft-versus-host disease (GvHD) when using allogeneic T cells.
CAR-NK is an important evolutionary direction addressing these limitations. NK cells don't need HLA matching with recipients and won't cause GvHD — allowing use of 'universal type' (off-the-shelf allogeneic) NK cells, manufactured in one batch, used for all patients, greatly reducing cost and waiting time. CRS risk from NK cells is far lower than CAR-T, better safety profile. NK cells simultaneously have CAR-targeted recognition (engineered) and natural activating receptor recognition (NKG2D, etc.), forming dual recognition mechanism, stronger resistance to tumor escape. Additionally, CAR-NK can be further engineered: secreting IL-15 (self-maintaining in the body, avoiding need for repeated infusions); knocking out NKG2A (releasing one of NK cells' major inhibitory receptors); expressing Fc receptor fusion proteins (through ADCC mechanism, synergizing with monoclonal antibodies for killing). MD Anderson Cancer Center's team (Katayoun Rezvani et al.) published the world's first CAR-NK clinical trial data in the New England Journal of Medicine in 2020, with seventy-three percent of patients in CD19+ blood tumor patients reaching remission, without severe CRS or GvHD — a milestone for CAR-NK entering clinical practice as a 'safer CAR-T alternative.'
3. CRISPR immune engineering: more precisely rewriting cell fate
The maturation of CRISPR/Cas9 gene editing technology (Jennifer Doudna and Emmanuelle Charpentier won the 2020 Nobel Prize in Chemistry for this) provided immune engineering with unprecedented precision modification tools. Main CRISPR application directions in immune cell engineering: knocking out the PD-1 gene, so T cells are no longer suppressed by tumor PD-L1 signals, maintaining activity longer in the tumor microenvironment (multiple CRISPR-PD1 knockout T cell clinical trials are underway globally); knocking out TET2 (a DNA demethylase), significantly enhancing CAR-T cell persistence and anti-tumor effects in CAR-T cells (from a case report at the University of Pennsylvania: one CLL patient achieved complete remission after CRISPR-TET2 CAR-T treatment); creating universal (Universal) cell products by simultaneously knocking out T cell TCR (preventing GvHD) and HLA-A/B (preventing being cleared by recipient's immune system), creating 'off-the-shelf' CAR-T that can be used for any patient; and enhancing NK cell function by knocking out CISH (a cytokine signal suppressor that inhibits NK cell IL-15 signaling), significantly enhancing NK cell tumor killing capacity.
CRISPR immune engineering represents the evolution of immune engineering from 'installing new capabilities' (CAR) toward 'fully rewriting cell programs.' Its potential, theoretically, has almost no ceiling — any gene affecting immune cell function can be precisely edited.
|
CRISPR immune engineering's ultimate vision: not just giving immune cells a new weapon, but fully rewriting their gene programs, deleting weaknesses, enhancing strengths, creating an immune cell version that never existed in natural evolution. |
4. Bispecific antibodies: no need to modify cells — directly 'matchmake''
Immune engineering isn't only about modifying cells — it also includes designing engineered proteins that can redirect immune attacks in the body. Bispecific antibodies, as the name implies, simultaneously have two binding arms: one end binds to a tumor cell surface antigen (like CD19, CD33), the other end binds to T cell surface CD3 receptor. When both ends bind simultaneously, it 'pulls' T cells and tumor cells together, forming an immune synapse between them, forcing T cells to attack tumor cells — even if that T cell originally had no specific recognition capacity for this tumor. This strategy is called Bispecific T-cell Engager (BiTE). The first BiTE product, Blinatumomab (targeting CD19×CD3), was FDA approved in 2014, used for relapsed/refractory B-ALL. Subsequently multiple BiTE/bispecific antibodies have been approved or entered late-stage clinical use, covering multiple myeloma, non-Hodgkin's lymphoma, acute myeloid leukemia, and other blood tumors.
5. Challenges facing immune engineering: solid tumors, resistance, and manufacturing
Immune engineering has achieved exciting results in blood tumors, but in solid tumors (lung cancer, colorectal cancer, breast cancer — most cancer types), challenges are far greater: tumor homing problem — in blood tumors, CAR-T and CAR-NK can freely circulate to reach tumor cells; in solid tumors, immune cells need to penetrate the tumor's stromal barrier (CAFs, etc.) to reach the tumor core, and this barrier is very difficult to penetrate; TME's metabolic suppression — low glucose, high lactate, adenosine and other metabolic factors rapidly inactivate CAR-T and CAR-NK entering solid tumors; target antigen diversity — solid tumor antigen expression is heterogeneous, single antigen targeting easily leads to escape of antigen-negative tumor cells; manufacturing cost and scale — CAR-T requires individualized manufacturing per batch, cost is extremely high (~$300,000–500,000 per treatment), limiting widespread application.
Research addressing these challenges is advancing rapidly: universal off-the-shelf CAR-NK (solving manufacturing cost problem); metabolically enhanced engineered immune cells (solving TME metabolic suppression); multi-antigen targeting CARs (solving tumor escape); and oncolytic viruses combined with CAR cells (solving homing and TME remodeling). Immune engineering is a rapidly evolving field — the limitations that exist when this is written may be partially solved within five years.
Frequently Asked Questions